{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:46:19Z","timestamp":1790768779876,"version":"4.1.0"},"reference-count":216,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1124\/dmd.114.062174","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T07:00:56Z","timestamp":1421218856000},"page":"490-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":132,"title":["Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design"],"prefix":"10.1016","volume":"43","author":[{"given":"Caroline A","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meeghan A","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasha K","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Galetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack A","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ragueneau-Majlessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harma","family":"Ellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F","family":"Paine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej J","family":"Zamek-Gliszczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.114.062174_bib1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/jcpt.12047","article-title":"Colchicine toxicity precipitated by interaction with sunitinib","volume":"38","author":"Abodunde","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"10.1124\/dmd.114.062174_bib2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/jps.21860","article-title":"Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration","volume":"99","author":"Adkison","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.114.062174_bib3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2125.2008.03184.x","article-title":"The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects","volume":"66","author":"Adkison","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib4","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1158\/1535-7163.MCT-12-0552","article-title":"Active efflux of dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents","volume":"11","author":"Agarwal","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.114.062174_bib5","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1158\/0008-5472.CAN-04-1817","article-title":"Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2","volume":"65","author":"Ahmed-Belkacem","year":"2005","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.114.062174_bib6","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/00498254.2013.840750","article-title":"Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases","volume":"44","author":"Ai","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.114.062174_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2125.2011.03972.x","article-title":"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers","volume":"72","author":"Allred","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib8","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1124\/dmd.107.014969","article-title":"Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones","volume":"35","author":"Ando","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.tox.2007.03.007","article-title":"Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products","volume":"235","author":"Appiah-Opong","year":"2007","journal-title":"Toxicology"},{"key":"10.1124\/dmd.114.062174_bib10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2133\/dmpk.DMPK-11-NT-068","article-title":"ABCG2 modulates chlorothiazide permeability\u2014in vitro-characterization of its interactions","volume":"27","author":"Be\u00e9ry","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.114.062174_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/B:DRUG.0000047104.45929.ea","article-title":"Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects","volume":"23","author":"Bence","year":"2005","journal-title":"Invest New Drugs"},{"key":"10.1124\/dmd.114.062174_bib12","doi-asserted-by":"crossref","first-page":"e71266","DOI":"10.1371\/journal.pone.0071266","article-title":"The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions","volume":"8","author":"Bhullar","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/dmd.114.062174_bib13","first-page":"51","article-title":"Pantoprazole does not interact with nifedipine in man under steady-state conditions","volume":"34","author":"Bliesath","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1124\/dmd.114.062174_bib14","first-page":"S81","article-title":"Pantoprazole does not interact with nifedipine in man under steady-state conditions","volume":"34","author":"Bliesath","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1124\/dmd.114.062174_bib15","first-page":"S76","article-title":"Lack of pharmacokinetic interaction between pantoprazole and diclofenac","volume":"34","author":"Bliesath","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib16","first-page":"152","article-title":"Lack of pharmacokinetic interaction between pantoprazole and diclofenac","volume":"34","author":"Bliesath","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00280-010-1507-6","article-title":"A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)","volume":"67","author":"Bullock","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/FJC.0b013e31817b5b5a","article-title":"Effects of atazanavir\/ritonavir or fosamprenavir\/ritonavir on the pharmacokinetics of rosuvastatin","volume":"51","author":"Busti","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/dmd.111.040949","article-title":"Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity","volume":"40","author":"Castellino","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib20","first-page":"4048","article-title":"Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport","volume":"63","author":"Chen","year":"2003","journal-title":"Cancer Res"},{"issue":"4B","key":"10.1124\/dmd.114.062174_bib21","first-page":"2895","article-title":"Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions","volume":"21","author":"Cheng","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1124\/dmd.114.062174_bib22","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.2013.52.1161","article-title":"Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer","volume":"32","author":"Chien","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.114.062174_bib23","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.2042-7158.2012.01498.x","article-title":"Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil","volume":"64","author":"Choi","year":"2012","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1124\/dmd.112.049668","article-title":"In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters","volume":"41","author":"Chu","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/clpt.2013.78","article-title":"Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver","volume":"94","author":"Chu","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib26","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3109\/00498254.2011.643256","article-title":"The impact of P-glycoprotein mediated efflux on absorption of 11 sedating and less-sedating antihistamines using Caco-2 monolayers","volume":"42","author":"Crowe","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.114.062174_bib27","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/jnci\/djj469","article-title":"Pharmacogenetics of ABCG2 and adverse reactions to gefitinib","volume":"98","author":"Cusatis","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/dmd.114.062174_bib28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/jcph.256","article-title":"Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin","volume":"54","author":"Custodio","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib29","doi-asserted-by":"crossref","first-page":"G371","DOI":"10.1152\/ajpgi.00102.2009","article-title":"Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting","volume":"297","author":"Dahan","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/dmd.114.062174_bib30","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1158\/1078-0432.CCR-04-0144","article-title":"ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition","volume":"10","author":"de Jong","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.114.062174_bib31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/FPC.0b013e328360d10c","article-title":"ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein","volume":"23","author":"Dickens","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.114.062174_bib32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/aps.2010.218","article-title":"Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib","volume":"32","author":"Dong","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/dmd.114.062174_bib33","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-2125.1995.tb05732.x","article-title":"Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin","volume":"39","author":"Duursema","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMp1106689","article-title":"Weighing the benefits of high-dose simvastatin against the risk of myopathy","volume":"365","author":"Egan","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.114.062174_bib35","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/clpt.2012.163","article-title":"Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it\u2019s not just about OATP1B1","volume":"92","author":"Elsby","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib36","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3109\/00498254.2011.578761","article-title":"Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions","volume":"41","author":"Elsby","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.114.062174_bib37","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejps.2005.11.002","article-title":"The role of transporters in drug interactions","volume":"27","author":"Endres","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.114.062174_bib38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/dmd.113.054932","article-title":"Cytochrome p450 inhibitory properties of common efflux transporter inhibitors","volume":"42","author":"Englund","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ejps.2006.04.010","article-title":"Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells","volume":"29","author":"Englund","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.114.062174_bib40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/dmd.106.012567","article-title":"Involvement of breast cancer resistance protein (BCRP\/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect","volume":"35","author":"Enokizono","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib41","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1124\/dmd.106.011239","article-title":"Regional expression and activity of breast cancer resistance protein (Bcrp\/Abcg2) in mouse intestine: overlapping distribution with sulfotransferases","volume":"35","author":"Enokizono","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib42","series-title":"Guideline on the Investigation of Drug Interactions","year":"2013"},{"key":"10.1124\/dmd.114.062174_bib43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/dmd.111.041665","article-title":"Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study","volume":"40","author":"Farrell","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib44","first-page":"520","article-title":"[The measurement of bronchial hyperreactivity for military service fitness]","volume":"82","author":"Ferrante","year":"1991","journal-title":"Recenti Prog Med"},{"key":"10.1124\/dmd.114.062174_bib45","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/1756-0500-6-445","article-title":"Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein","volume":"6","author":"Fujita","year":"2013","journal-title":"BMC Res Notes"},{"key":"10.1124\/dmd.114.062174_bib46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11095-008-9752-7","article-title":"Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations","volume":"26","author":"Furukawa","year":"2009","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.114.062174_bib47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1055-9965.120.14.1","article-title":"Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences","volume":"14","author":"Garcea","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1124\/dmd.114.062174_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/clpt.2013.12","article-title":"International Transporter Consortium commentary on clinically important transporter polymorphisms","volume":"94","author":"Giacomini","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.114.062174_bib50","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bcpt.12005","article-title":"Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry","volume":"112","author":"Gong","year":"2013","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.114.062174_bib51","series-title":"Goodman & Gilman's the Pharmacological Basis of Therapeutics","author":"Goodman","year":"2005"},{"key":"10.1124\/dmd.114.062174_bib52","series-title":"Goodman & Gilman's the Pharmacological Basis of Therapeutics","author":"Goodman","year":"2001"},{"key":"10.1124\/dmd.114.062174_bib53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2125.1996.40619.x","article-title":"Lack of pharmacokinetic interaction of pantoprazole with diazepam in man","volume":"42","author":"Gugler","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2125.1996.04038.x","article-title":"Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response","volume":"42","author":"Haagsma","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib55","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/cncr.22760","article-title":"Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer","volume":"110","author":"Han","year":"2007","journal-title":"Cancer"},{"key":"10.1124\/dmd.114.062174_bib56","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1124\/dmd.109.031518","article-title":"Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters","volume":"38","author":"Han","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib57","first-page":"481","article-title":"Lack of interaction between pantoprazole and digoxin at therapeutic doses in man","volume":"33","author":"Hartmann","year":"1995","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1124\/dmd.114.062174_bib58","first-page":"S67","article-title":"Lack of interaction between pantoprazole and digoxin at therapeutic doses in man","volume":"34","author":"Hartmann","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib59","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3109\/00498254.2012.697590","article-title":"Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism","volume":"42","author":"He","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.114.062174_bib60","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bcp.2010.06.025","article-title":"Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion","volume":"80","author":"Hemauer","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib61","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1124\/mol.105.014019","article-title":"Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin","volume":"68","author":"Hirano","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib62","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","article-title":"Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics","volume":"130","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.114.062174_bib63","doi-asserted-by":"crossref","first-page":"e75520","DOI":"10.1371\/journal.pone.0075520","article-title":"Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1)","volume":"8","author":"Hofman","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/dmd.114.062174_bib64","first-page":"521","article-title":"Pantoprazole does not interact with the pharmacokinetics of carbamazepine","volume":"36","author":"Huber","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib65","first-page":"4595","article-title":"In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative","volume":"53","author":"Hyafil","year":"1993","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.114.062174_bib66","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.clpt.6100190","article-title":"SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers","volume":"82","author":"Ieiri","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib67","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/mol.64.3.610","article-title":"Breast cancer resistance protein exports sulfated estrogens but not free estrogens","volume":"64","author":"Imai","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib68","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/0008-5472.CAN-04-0078","article-title":"Phytoestrogens\/flavonoids reverse breast cancer resistance protein\/ABCG2-mediated multidrug resistance","volume":"64","author":"Imai","year":"2004","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.114.062174_bib69","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1211\/0022357043914","article-title":"Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations","volume":"56","author":"Itagaki","year":"2004","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib70","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1349-7006.2007.00541.x","article-title":"Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients","volume":"98","author":"Jada","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1124\/dmd.114.062174_bib71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40262-013-0097-y","article-title":"A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine","volume":"53","author":"Jamei","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.114.062174_bib72","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/jps.22262","article-title":"Ivermectin interacts with human ABCG2","volume":"100","author":"Jani","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.114.062174_bib73","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1248\/bpb.32.497","article-title":"Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2","volume":"32","author":"Jani","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.114.062174_bib74","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/00498254.2012.720740","article-title":"Transport of gemifloxacin, a 4th generation quinolone antibiotic, in the Caco-2 and engineered MDCKII cells, and potential involvement of efflux transporters in the intestinal absorption of the drug","volume":"43","author":"Jin","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.114.062174_bib75","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1124\/dmd.111.042994","article-title":"Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data","volume":"40","author":"Jones","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib76","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/jnci\/92.20.1651","article-title":"Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan","volume":"92","author":"Jonker","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/dmd.114.062174_bib77","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00228-007-0298-0","article-title":"Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers","volume":"63","author":"Juan","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib78","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/clpt.2013.34","article-title":"Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position","volume":"94","author":"Kalvass","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib79","article-title":"Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates","author":"Karibe","year":"2014","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.114.062174_bib80","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11095-011-0564-9","article-title":"In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions","volume":"29","author":"Karlgren","year":"2012","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.114.062174_bib81","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/jm300212s","article-title":"Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions","volume":"55","author":"Karlgren","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.114.062174_bib82","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1349-7006.2010.01539.x","article-title":"Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP\/ABCG2 gene","volume":"101","author":"Kawahara","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1124\/dmd.114.062174_bib83","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s11095-012-0724-6","article-title":"Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction","volume":"29","author":"Kenny","year":"2012","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.114.062174_bib84","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/pgs.09.85","article-title":"Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin","volume":"10","author":"Keskitalo","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.114.062174_bib85","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","article-title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib86","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2007.02944.x","article-title":"The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine","volume":"64","author":"Kim","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib87","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2133\/dmpk.DMPK-13-RG-019","article-title":"The tyrosine kinase inhibitor nilotinib selectively inhibits CYP2C8 activities in human liver microsomes","volume":"28","author":"Kim","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.114.062174_bib88","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/QAI.0b013e318160a542","article-title":"Drug\/drug interaction between lopinavir\/ritonavir and rosuvastatin in healthy volunteers","volume":"47","author":"Kiser","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.114.062174_bib89","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib90","first-page":"420","article-title":"Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers","volume":"34","author":"Koch","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib91","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1023\/B:PHAM.0000045245.21637.d4","article-title":"Functional analysis of SNPs variants of BCRP\/ABCG2","volume":"21","author":"Kondo","year":"2004","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.114.062174_bib92","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2002.12.116","article-title":"Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918","volume":"20","author":"Kruijtzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.114.062174_bib93","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1158\/1078-0432.CCR-06-2414","article-title":"A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients","volume":"13","author":"Kuppens","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.114.062174_bib94","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1476-5381.2012.01887.x","article-title":"Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP","volume":"166","author":"Kusuhara","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib95","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1535-7163.MCT-09-0663","article-title":"Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation","volume":"9","author":"Lagas","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.114.062174_bib96","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.4161\/cc.22382","article-title":"Erlotinib antagonizes ABC transporters in acute myeloid leukemia","volume":"11","author":"Lainey","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1124\/dmd.114.062174_bib216","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2217\/pgs.13.115","article-title":"Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9\/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients","volume":"14","author":"Lee","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1124\/dmd.114.062174_bib97","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1158\/0008-5472.CAN-05-2915","article-title":"Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo","volume":"66","author":"Leggas","year":"2006","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.114.062174_bib98","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s11095-008-9678-0","article-title":"Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells","volume":"25","author":"Li","year":"2008","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.114.062174_bib99","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1124\/dmd.111.038075","article-title":"Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs","volume":"39","author":"Li","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib100","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1124\/dmd.112.045666","article-title":"The role of a basolateral transporter in rosuvastatin transport and its interplay with apical breast cancer resistance protein in polarized cell monolayer systems","volume":"40","author":"Li","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib101","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1124\/dmd.111.039370","article-title":"pH-Dependent transport of pemetrexed by breast cancer resistance protein","volume":"39","author":"Li","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib102","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1208\/s12248-014-9616-5","article-title":"Permeability comparison between hepatocyte and low efflux MDCKII cell monolayer","volume":"16","author":"Li","year":"2014","journal-title":"AAPS J"},{"key":"10.1124\/dmd.114.062174_bib103","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1124\/dmd.109.030361","article-title":"Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile","volume":"38","author":"Li","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib104","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/dmd.110.034629","article-title":"Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model","volume":"39","author":"Lin","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib106","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/dmd.109.029660","article-title":"Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases","volume":"38","author":"Liu","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib107","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s002280000173","article-title":"The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients","volume":"56","author":"Lorf","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib108","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1517\/14740338.2011.533168","article-title":"Lapatinib for breast cancer: a review of the current literature","volume":"10","author":"MacFarlane","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1124\/dmd.114.062174_bib109","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1124\/dmd.108.020859","article-title":"Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats","volume":"36","author":"MacLean","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib110","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ejca.2012.09.036","article-title":"A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours","volume":"49","author":"Macpherson","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1124\/dmd.114.062174_bib111","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1054\/bjoc.2000.1543","article-title":"Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients","volume":"84","author":"Malingr\u00e9","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.114.062174_bib112","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1208\/aapsj070112","article-title":"Role of the breast cancer resistance protein (ABCG2) in drug transport","volume":"7","author":"Mao","year":"2005","journal-title":"AAPS J"},{"key":"10.1124\/dmd.114.062174_bib113","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10637-013-9923-1","article-title":"Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA","volume":"31","author":"Marchetti","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1124\/dmd.114.062174_bib114","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/S0149-2918(03)80316-8","article-title":"Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers","volume":"25","author":"Martin","year":"2003","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.114.062174_bib115","doi-asserted-by":"crossref","first-page":"5ra11","DOI":"10.1126\/scitranslmed.3000237","article-title":"Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population","volume":"1","author":"Matsuo","year":"2009","journal-title":"Sci Transl Med"},{"key":"10.1124\/dmd.114.062174_bib116","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1124\/dmd.112.046193","article-title":"Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes","volume":"40","author":"M\u00e9nochet","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib117","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1124\/dmd.105.008219","article-title":"Breast cancer resistance protein (BCRP\/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion","volume":"34","author":"Merino","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib118","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s11095-010-0208-5","article-title":"In vivo inhibition of BCRP\/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-\/-) mice","volume":"27","author":"Merino","year":"2010","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.114.062174_bib119","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1158\/1078-0432.CCR-04-0746","article-title":"Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities","volume":"10","author":"Messersmith","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.114.062174_bib120","first-page":"304","article-title":"No influence of pantoprazole on the pharmacokinetics of phenytoin","volume":"33","author":"Middle","year":"1995","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1124\/dmd.114.062174_bib121","first-page":"S72","article-title":"No influence of pantoprazole on the pharmacokinetics of phenytoin","volume":"34","author":"Middle","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib122","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/annonc\/mdm366","article-title":"A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan","volume":"18","author":"Midgley","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1124\/dmd.114.062174_bib123","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/cncr.22816","article-title":"Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer","volume":"110","author":"Milton","year":"2007","journal-title":"Cancer"},{"key":"10.1124\/dmd.114.062174_bib124","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1535-7163.MCT-10-0731","article-title":"Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins","volume":"10","author":"Minematsu","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.114.062174_bib125","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1124\/dmd.107.016352","article-title":"Evaluation of the role of breast cancer resistance protein (BCRP\/ABCG2) and multidrug resistance-associated protein 4 (MRP4\/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one)","volume":"35","author":"Mizuno","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib126","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.1158\/1078-0432.CCR-08-0415","article-title":"Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data","volume":"14","author":"Molina","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.114.062174_bib127","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jat\/bkt060","article-title":"In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors","volume":"37","author":"Moody","year":"2013","journal-title":"J Anal Toxicol"},{"key":"10.1124\/dmd.114.062174_bib128","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/bdd.1801","article-title":"Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier","volume":"33","author":"Nagasaka","year":"2012","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.114.062174_bib129","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1006\/bbrc.2001.5850","article-title":"Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells","volume":"288","author":"Nakatomi","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.114.062174_bib130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/138920010792927325","article-title":"Structure and function of the human breast cancer resistance protein (BCRP\/ABCG2)","volume":"11","author":"Ni","year":"2010","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.114.062174_bib131","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1349-7006.2009.01213.x","article-title":"Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib","volume":"100","author":"Noguchi","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1124\/dmd.114.062174_bib132","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1124\/jpet.113.208959","article-title":"Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain","volume":"347","author":"Oberoi","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.062174_bib133","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/jps.22628","article-title":"Evaluation of transport mechanism of prodrugs and parent drugs formed by intracellular metabolism in Caco-2 cells with modified carboxylesterase activity: temocapril as a model case","volume":"100","author":"Ohura","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.114.062174_bib134","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1124\/dmd.108.024901","article-title":"Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and\/or ABCG2 inhibitors","volume":"37","author":"Oostendorp","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib135","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1021\/mp300547h","article-title":"Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening","volume":"10","author":"Pan","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.114.062174_bib136","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1124\/dmd.31.12.1507","article-title":"Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series)","volume":"31","author":"Pang","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib137","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib138","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","article-title":"Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein","volume":"364","author":"Pauli-Magnus","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib139","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1124\/jpet.104.073916","article-title":"Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine","volume":"312","author":"Pavek","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.062174_bib140","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1124\/jpet.113.208314","article-title":"Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver","volume":"347","author":"Pfeifer","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.062174_bib141","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1124\/jpet.113.207472","article-title":"Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes","volume":"347","author":"Pfeifer","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.062174_bib142","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1128\/AAC.00449-09","article-title":"Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers","volume":"53","author":"Pham","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.114.062174_bib143","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00280-004-0854-6","article-title":"A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors","volume":"55","author":"Planting","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib144","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1124\/dmd.114.058248","article-title":"The need for human breast cancer resistance protein substrate and inhibition evaluation in drug discovery and development: why, when, and how?","volume":"42","author":"Poirier","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib145","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1124\/dmd.109.030791","article-title":"Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A\/Q141K BCRP single-nucleotide polymorphism","volume":"38","author":"Pollex","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib146","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/dmd.107.018374","article-title":"The role of efflux and uptake transporters in [N-3-chloro-4-[(3-fluorobenzyl)oxy]phenyl-6-[5-([2-(methylsulfonyl)ethyl]aminomethyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions","volume":"36","author":"Polli","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib147","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12377","article-title":"Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin","volume":"78","author":"Prueksaritanont","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib148","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000327372","article-title":"Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report\u2014should the practice be changed?","volume":"57","author":"Ranchon","year":"2011","journal-title":"Chemotherapy"},{"key":"10.1124\/dmd.114.062174_bib149","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib150","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrrheum.2012.144","article-title":"The genetics of hyperuricaemia and gout","volume":"8","author":"Reginato","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1124\/dmd.114.062174_bib151","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40261-013-0135-4","article-title":"Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study","volume":"34","author":"Remes-Troche","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1124\/dmd.114.062174_bib152","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1124\/dmd.113.051193","article-title":"In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions","volume":"41","author":"Reyner","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib153","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00280-009-1209-0","article-title":"Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study","volume":"66","author":"Robert","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib154","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2174\/138920111795163913","article-title":"The challenge of exploiting ABCG2 in the clinic","volume":"12","author":"Robey","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1124\/dmd.114.062174_bib155","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/ng.1070","article-title":"Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior","volume":"44","author":"Saison","year":"2012","journal-title":"Nat Genet"},{"key":"10.1124\/dmd.114.062174_bib156","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1124\/jpet.105.099036","article-title":"A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions","volume":"317","author":"Saito","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.062174_bib157","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.ejca.2005.05.009","article-title":"Curcumin: the story so far","volume":"41","author":"Sharma","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1124\/dmd.114.062174_bib158","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.1823","article-title":"Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption","volume":"34","author":"Shitara","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.114.062174_bib159","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1021\/mp400762h","article-title":"Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach","volume":"11","author":"Shukla","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.114.062174_bib160","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11095-008-9735-8","article-title":"Curcumin inhibits the activity of ABCG2\/BCRP1, a multidrug resistance-linked ABC drug transporter in mice","volume":"26","author":"Shukla","year":"2009","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.114.062174_bib161","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.3760\/cma.j.issn.0366-6999.20130950","article-title":"Reversion effects of curcumin on multidrug resistance of MNNG\/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein","volume":"126","author":"Si","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"10.1124\/dmd.114.062174_bib162","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","article-title":"Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine","volume":"76","author":"Simonson","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib163","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clpt.2004.03.003","article-title":"Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype","volume":"76","author":"Sparreboom","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib164","doi-asserted-by":"crossref","first-page":"650","DOI":"10.4161\/cbt.4.6.1731","article-title":"Effect of ABCG2 genotype on the oral bioavailability of topotecan","volume":"4","author":"Sparreboom","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1124\/dmd.114.062174_bib165","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-014-2385-0","article-title":"Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors","volume":"73","author":"Stewart","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib166","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1002\/jps.22652","article-title":"Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage","volume":"100","author":"Sugimoto","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.114.062174_bib167","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2125.2008.03303.x","article-title":"Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy","volume":"67","author":"Suzuki","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib168","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2165\/00003088-200544100-00005","article-title":"Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol","volume":"44","author":"Swaisland","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.114.062174_bib169","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2133\/dmpk.25.170","article-title":"Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids","volume":"25","author":"Tamaki","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.114.062174_bib170","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/mol.106.023556","article-title":"Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport","volume":"70","author":"Tamura","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib171","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/trf.12277","article-title":"Defining the Jr(a-) phenotype in the Japanese population","volume":"54","author":"Tanaka","year":"2014","journal-title":"Transfusion"},{"key":"10.1124\/dmd.114.062174_bib172","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ijc.26000","article-title":"Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration","volume":"130","author":"Tang","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1124\/dmd.114.062174_bib173","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1124\/jpet.111.186908","article-title":"P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib","volume":"341","author":"Tang","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.062174_bib174","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.2146\/ajhp090202","article-title":"Elevated international normalized ratio associated with concomitant warfarin and erlotinib","volume":"67","author":"Thomas","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"10.1124\/dmd.114.062174_bib175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcp.2009.04.002","article-title":"Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1\/Pgp and ABCG2\/BCRP\/MXR transporters","volume":"78","author":"Tiwari","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib176","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2133\/dmpk.DMPK-12-NT-024","article-title":"Studies on the intestinal absorption characteristics of sulfasalazine, a breast cancer resistance protein (BCRP) substrate","volume":"28","author":"Tomaru","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.114.062174_bib177","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10637-009-9380-z","article-title":"Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced non-small cell lung cancer (NSCLC)","volume":"29","author":"Tran","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1124\/dmd.114.062174_bib178","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/clpt.2014.55","article-title":"Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach","volume":"96","author":"Tsamandouras","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib179","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/FPC.0b013e3282f974dc","article-title":"Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe","volume":"18","author":"Urquhart","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.114.062174_bib180","series-title":"Guidance for Industry: Drug Interaction Studies\u2014Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations","year":"2012"},{"key":"10.1124\/dmd.114.062174_bib181","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1124\/dmd.112.049023","article-title":"Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1","volume":"41","author":"van de Steeg","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib182","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1208\/s12248-014-9614-7","article-title":"Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide","volume":"16","author":"Varma","year":"2014","journal-title":"AAPS J"},{"key":"10.1124\/dmd.114.062174_bib183","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3816\/CLC.2008.n.036","article-title":"Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin","volume":"9","author":"Veeraputhiran","year":"2008","journal-title":"Clin Lung Cancer"},{"key":"10.1124\/dmd.114.062174_bib184","first-page":"5538","article-title":"Wild-type breast cancer resistance protein (BCRP\/ABCG2) is a methotrexate polyglutamate transporter","volume":"63","author":"Volk","year":"2003","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.114.062174_bib185","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/dmd.111.041616","article-title":"Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis","volume":"40","author":"Wang","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib186","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijpharm.2007.12.024","article-title":"Application and limitation of inhibitors in drug-transporter interactions studies","volume":"356","author":"Wang","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1124\/dmd.114.062174_bib187","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/dmd.113.053793","article-title":"Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials","volume":"42","author":"Wang","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib188","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1021\/mp4005595","article-title":"Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility","volume":"10","author":"Ware","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.114.062174_bib189","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/jpet.108.146647","article-title":"Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans","volume":"328","author":"Watanabe","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.114.062174_bib190","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/mp300562q","article-title":"Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells","volume":"10","author":"Wei","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.114.062174_bib191","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ijantimicag.2013.01.004","article-title":"Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro","volume":"41","author":"Weiss","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/dmd.114.062174_bib192","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cncr.21831","article-title":"Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer","volume":"106","author":"Wilding","year":"2006","journal-title":"Cancer"},{"key":"10.1124\/dmd.114.062174_bib193","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejphar.2011.10.004","article-title":"Breast cancer resistance protein BCRP (ABCG2)-mediated transepithelial nitrofurantoin secretion and its regulation in human intestinal epithelial (Caco-2) layers","volume":"672","author":"Wright","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib194","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/dmd.106.011866","article-title":"Interactions of cyclosporin a with breast cancer resistance protein","volume":"35","author":"Xia","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib195","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/dmd.111.043703","article-title":"Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates","volume":"40","author":"Xiao","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib196","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1021\/mp050088t","article-title":"A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line","volume":"3","author":"Xiao","year":"2006","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.114.062174_bib197","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-007-0494-8","article-title":"Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors","volume":"61","author":"Yamamoto","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.114.062174_bib198","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.clpt.6100459","article-title":"Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans","volume":"84","author":"Yamasaki","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.114.062174_bib199","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1158\/1535-7163.1119.3.9","article-title":"Gefitinib reverses breast cancer resistance protein-mediated drug resistance","volume":"3","author":"Yanase","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.114.062174_bib200","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/187231210792928279","article-title":"P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor","volume":"4","author":"Yang","year":"2010","journal-title":"Drug Metab Lett"},{"key":"10.1124\/dmd.114.062174_bib201","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.toxlet.2012.11.011","article-title":"The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells","volume":"216","author":"Ye","year":"2013","journal-title":"Toxicol Lett"},{"key":"10.1124\/dmd.114.062174_bib202","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/11538700-000000000-00000","article-title":"Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects","volume":"31","author":"Yin","year":"2011","journal-title":"Clin Drug Investig"},{"key":"10.1124\/dmd.114.062174_bib203","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1124\/dmd.107.019513","article-title":"Inhibitory effects of terpenoids on multidrug resistance-associated protein 2- and breast cancer resistance protein-mediated transport","volume":"36","author":"Yoshida","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib204","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/mp050113v","article-title":"Breast cancer resistance protein (Bcrp\/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse","volume":"3","author":"Zaher","year":"2006","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.114.062174_bib205","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1124\/dmd.112.046508","article-title":"Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics","volume":"40","author":"Zamek-Gliszczynski","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib206","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ng.1075","article-title":"ABCG2 null alleles define the Jr(a-) blood group phenotype","volume":"44","author":"Zelinski","year":"2012","journal-title":"Nat Genet"},{"key":"10.1124\/dmd.114.062174_bib207","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1124\/dmd.112.050260","article-title":"Characterization of efflux transporters involved in distribution and disposition of apixaban","volume":"41","author":"Zhang","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib208","series-title":"Drug Metabolism in Drug Design and Development: Basic Concepts and Practice","author":"Zhang","year":"2008"},{"key":"10.1124\/dmd.114.062174_bib209","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1124\/dmd.104.002501","article-title":"Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a\/1b (-\/-) mice","volume":"33","author":"Zhang","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2006.05.010","article-title":"Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males","volume":"373","author":"Zhang","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1124\/dmd.114.062174_bib211","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s11095-005-8384-4","article-title":"BCRP transports dipyridamole and is inhibited by calcium channel blockers","volume":"22","author":"Zhang","year":"2005","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.114.062174_bib212","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1124\/dmd.108.024489","article-title":"The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice","volume":"37","author":"Zhou","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.114.062174_bib213","first-page":"187","article-title":"CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics","volume":"68","author":"Zhou","year":"2013","journal-title":"Pharmazie"},{"key":"10.1124\/dmd.114.062174_bib214","first-page":"133","article-title":"An open-label, non-comparative, non-interventional, multi-center, post-authorization safety study on the administration of rabeprazole to adults with gastro-esophageal reflux disease","volume":"27","author":"Zouboulis-Vafiadis","year":"2014","journal-title":"Ann Gastroenterol"},{"key":"10.1124\/dmd.114.062174_bib215","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.112.045575","article-title":"Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19","volume":"40","author":"Zvyaga","year":"2012","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562410267X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562410267X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.114.062174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:26:19Z","timestamp":1739906779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562410267X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":216,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S009095562410267X"],"URL":"https:\/\/doi.org\/10.1124\/dmd.114.062174","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.114.062174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}